These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 1242657)

  • 1. [MASCA-model of the biochemical-pharmacological drug research. Part 3: Structure-activity relationships and KANORA (author's transl)].
    Mager PP
    Arzneimittelforschung; 1975 Sep; 25(9):1355-6. PubMed ID: 1242657
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [MASCA-model of the biochemical-pharmacological drug research/ part 4: Structure-activity relationships and MANOVA (author's transl)].
    Mager PP
    Arzneimittelforschung; 1975 Oct; 25(10):1475-6. PubMed ID: 1243023
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [MASCA-model of the biochemical-pharmacological drug research / part 5: Structure-activity relationships and MACOVA (author's transl)].
    Mager PP
    Arzneimittelforschung; 1975 Nov; 25(11):1745. PubMed ID: 1243081
    [No Abstract]   [Full Text] [Related]  

  • 4. [MASCA-model of biochemical-pharmacological drug research/Part VIII: Examples (author's transl)].
    Mager PP
    Arzneimittelforschung; 1976 Feb; 26(2):185-7. PubMed ID: 7279
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [MASCA-model of biochemical-pharmacological drug research. Part 6: Structure-activity relationship and bio-oscillations (author's transl)].
    Mager PP
    Arzneimittelforschung; 1975; 25(12):1864-5. PubMed ID: 1243656
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [MASCA-model of the biochemical-pharmacological drug research. Part 2: Multivariate test criterions and methods (author's transl)].
    Mager PP
    Arzneimittelforschung; 1975 Aug; 25(8):1270-2. PubMed ID: 1242357
    [No Abstract]   [Full Text] [Related]  

  • 7. [MASCA-Model of biochemical-pharmacological drug research/part 7: Computing scheme for the MASCA-model (author's transl)].
    Mager PP
    Arzneimittelforschung; 1976; 26(1):26-8. PubMed ID: 947168
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [MASCA-model of the biochemical-pharmacological drug research/part 1: Principle of the univariate structure-activity relationship and definitions of physico-chemical parameters (author's transl)].
    Mager PP
    Arzneimittelforschung; 1975 Jul; 25(7):1006-8. PubMed ID: 1174406
    [No Abstract]   [Full Text] [Related]  

  • 9. [A method for describing monotonic dose-effect curves and areas in yes/no reactions (author's transl)].
    Safer A
    Arzneimittelforschung; 1978; 28(9):1512-5. PubMed ID: 582546
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [On the calculation and the evaluation of combinations of active substances (author's transl)].
    Groeger U; Lang S; Michel HJ
    Pharmazie; 1981; 36(2):81-7. PubMed ID: 7232493
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Current problems in effective-substance research. 9. Parameter-free methods for the structure-activity analysis].
    Gäbler E; Franke R; Oehme P
    Pharmazie; 1976; 31(1):1-14. PubMed ID: 768997
    [No Abstract]   [Full Text] [Related]  

  • 12. [Multivariate Free-Wilson analysis (author's transl)].
    Mager PP; Seese A
    Pharmazie; 1981 Jun; 36(6):427-9. PubMed ID: 7279991
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug bioassay, synergy and quantitative structure activity relationships.
    Beezer AE
    Tokai J Exp Clin Med; 1990 Sep; 15(5):369-72. PubMed ID: 2131642
    [No Abstract]   [Full Text] [Related]  

  • 14. Pharmacological activities of a homologous series of pyrazole derivatives including quantitative structure-activity relationships (QSAR).
    Paintz M; Bekemeier H; Metzner J; Wenzel U
    Agents Actions Suppl; 1982; 10():47-58. PubMed ID: 6126091
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A characterization on misspecification in the general linear regression model.
    Rosenberg SH; Levy PS
    Biometrics; 1972 Dec; 28(4):1129-33. PubMed ID: 4648794
    [No Abstract]   [Full Text] [Related]  

  • 16. [Statistical evaluation of dynamic changes of laboratory parameters in the course of intermittent drug administration (author's transl)].
    Kubácek L
    Bratisl Lek Listy; 1974 Sep; 62(3):273-82. PubMed ID: 4410972
    [No Abstract]   [Full Text] [Related]  

  • 17. Structure-based approach to pharmacophore identification, in silico screening, and three-dimensional quantitative structure-activity relationship studies for inhibitors of Trypanosoma cruzi dihydrofolate reductase function.
    Schormann N; Senkovich O; Walker K; Wright DL; Anderson AC; Rosowsky A; Ananthan S; Shinkre B; Velu S; Chattopadhyay D
    Proteins; 2008 Dec; 73(4):889-901. PubMed ID: 18536013
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The monitoring of heparin administration by screening tests in experimental dogs.
    Mischke R; Jacobs C
    Res Vet Sci; 2001 Apr; 70(2):101-8. PubMed ID: 11356088
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Theoretical approaches to drug design and biological activity: II. Multivariate structure-activity relationships in combination with the multivariate bioassay (MASCA model).
    Mager PP
    Med Res Rev; 1983; 3(4):435-98. PubMed ID: 6358723
    [No Abstract]   [Full Text] [Related]  

  • 20. Quantitative structure-activity relationships within a series of melatonin analogs and related indolealkylamines.
    Lewis DF; Arendt J; English J
    J Pharmacol Exp Ther; 1990 Jan; 252(1):370-3. PubMed ID: 2153808
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.